Viking Therapeutics (NASDAQ:VKTX) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.
A number of other research analysts have also issued reports on the company. Maxim Group set a $8.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a report on Friday, November 10th. ValuEngine lowered Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Roth Capital initiated coverage on Viking Therapeutics in a report on Tuesday, November 21st. They set a “buy” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $7.00.
Viking Therapeutics (VKTX) opened at $6.17 on Thursday. The stock has a market capitalization of $286.53, a PE ratio of -7.35 and a beta of 2.26. Viking Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $7.15.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.